Cullinan Therapeutics(CGEM.US) Officer Sells US$130.64K in Common Stock

$Cullinan Therapeutics(CGEM.US)$ Officer Michaelson Jennifer sold 8,000 shares of common stock on Jul 5, 2024 at an average price of $16.33 for a total value of $130.64K.Source: Announcement What is

Moomoo NewsJul 9 18:10 ET

Institutional Owners May Ignore Cullinan Therapeutics, Inc.'s (NASDAQ:CGEM) Recent US$92m Market Cap Decline as Longer-term Profits Stay in the Green

Yahoo FinanceJun 4 08:52 ET

Stifel Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating, Maintains Target Price $40

Stifel analyst Bradley Canino maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 44.2% an

moomoo NewsJun 4 08:33 ET

TD Cowen Maintains Cullinan Therapeutics(CGEM.US) With Buy Rating

TD Cowen analyst Marc Frahm maintains $Cullinan Therapeutics(CGEM.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 47.0% and a total average return of 23.7% over th

moomoo NewsJun 4 08:33 ET

Express News | HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $28 Price Target

BenzingaJun 3 06:09 ET

Reported Saturday, Cullinan Therapeutics Announced Initial Data From Pivotal Phase 2b REZILIENT1 Study Of Zipalertinib

As of a January 12, 2024 data cut-off, 31 patients had been enrolled. Patients had received a median of three prior systemic anti-cancer regimens, including prior platinum-based chemotherapy, prior an

BenzingaJun 3 04:23 ET